ITCI Intracellular Th

USD 69.72 2.39 3.549681
Icon

Intracellular Th (ITCI) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - Specialty & Generic | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 69.72

+2.39 (+3.55)%

USD 6.68B

0.43M

USD 80.11(+14.90%)

USD 57.00 (-18.24%)

Icon

ITCI

Intracellular Th (USD)
COMMON STOCK | NSD
USD 69.72
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 6.68B

USD 57.00 (-18.24%)

USD 69.72

Intracellular Th (ITCI) Stock Forecast

USD 80.11
(+14.90%)

Based on the Intracellular Th stock forecast from 7 analysts, the average analyst target price for Intracellular Th is USD 80.11 over the next 12 months. Intracellular Th’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Intracellular Th is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Intracellular Th’s stock price was USD 69.72. Intracellular Th’s stock price has changed by +3.73% over the past week, -4.36% over the past month and +25.10% over the last year.

No recent analyst target price found for Intracellular Th
No recent average analyst rating found for Intracellular Th

Company Overview Intracellular Th

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mech...Read More

430 East 29th Street, New York, NY, United States, 10016

610

December

USD

USA

Adjusted Closing Price for Intracellular Th (ITCI)

Loading...

Unadjusted Closing Price for Intracellular Th (ITCI)

Loading...

Share Trading Volume for Intracellular Th Shares

Loading...

Compare Performance of Intracellular Th Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ITCI

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Intracellular Th (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VTRS
Viatris Inc +0.23 (+1.98%) USD14.11B 237.70 8.88

ETFs Containing ITCI

Symbol Name ITCI's Weight Expense Ratio Price(Change) Market Cap
PSIL
AdvisorShares Psychedelic.. 4.04 % 0.99 % +0.02 (+1.36%) USD7.46M

Frequently Asked Questions About Intracellular Th (ITCI) Stock

Based on ratings from 7 analysts Intracellular Th's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 8 buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on ITCI's stock to indicate if its a good dividend stock.

Based on targets from 7 analysts, the average taret price for ITCI is USD 80.11 over the next 12 months. The maximum analyst target price is USD 101 while the minimum anlayst target price is USD 64.

Unfortunately we do not have enough data on ITCI's stock to indicate if its overvalued.

The last closing price of ITCI's stock was USD 69.72.

The most recent market capitalization for ITCI is USD 6.68B.

Based on targets from 7 analysts, the average taret price for ITCI is projected at USD 80.11 over the next 12 months. This means that ITCI's stock price may go up by +14.90% over the next 12 months.

Following are ETFs with the highest allocation to Intracellular Th's stock :

PSIL

As per our most recent records Intracellular Th has 610 Employees.

Intracellular Th's registered address is 430 East 29th Street, New York, NY, United States, 10016. You can get more information about it from Intracellular Th's website at https://www.intracellulartherapies.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...